Australian Veterinary Stem Cell

Australian Veterinary Stem Cell (AVSC) was a specialized biotechnology firm based in Australia that focused on the development and commercialization of regenerative medicine for the veterinary market. Founded in 2007, the company developed a proprietary platform for adipose-derived mesenchymal stem cell therapies designed to treat inflammatory and degenerative conditions in animals. Its lead product candidates, CryoShot Canine and CryoShot Equine, were developed to address osteoarthritis and tendon injuries in dogs and horses, respectively. AVSC's foundational technology and operations were eventually rolled into Regeneus (now Cambium Bio) to facilitate the expansion into human therapeutic applications. The company's veterinary assets were later licensed to Virbac, a global leader in animal health, for international commercialization.